Patient Profile: Uncontrolled Type 2 diabetes with initial A1c of 15.7%
Medications:
- Mounjaro™
- Rosuvastatin
- Benazepril
Northwind Actions: Program addressed cost, behavioral barriers, and supported lasting improvements
NW Measures Taken:
- 13 pharmacist consultations
- Assisted in navigating GLP-1 side effects
- Health coaching support for lifestyle changes and motivation
Clinical Results:
- A1c trend: 8.8% Reduction in 6 months
- Upon program engagement in January 2023, hemoglobin A1c was 15.7%. With clinical guidance and medication navigation, this patient was able to stabilize their diabetes in June 2023 with an A1c of 7.1% and remains well controlled with a most recently reported A1c of 5.9%.
- 25 lbs weight loss
- BP and cholesterol controlled